Press "Enter" to skip to content

Anavex Life Sciences is participating in the BTIG Virtual Conference

Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders such as Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and other central nervous system (CNS) disorders, announced today that Christopher U. Missling, PhD, has been appointed as President and CEO.

The conference will be broadcast live on the Anavex corporate website at www.anavex.com in the Investors section under “Events.” Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company focused on the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders such as Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and other CNS diseases, as well as pain and cancer.

ANAVEX®2-73 (blarcamesine), Anavex’s flagship medication candidate, recently completed a Phase 2a Alzheimer’s disease clinical trial, as well as a Phase 2 proof-of-concept study in Parkinson’s disease dementia and a Phase 2 study in adult individuals with Rett syndrome. ANAVEX®2-73 is an orally accessible medication candidate that targets sigma-1 and muscarinic receptors to restore cellular equilibrium.Preclinical investigations have shown that it has the potential to slow or reverse the progression of Alzheimer’s disease. In animal models, ANAVEX®2-73 showed anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant characteristics, indicating that it could be used to treat other CNS illnesses including epilepsy.

Anavex previously received a research grant from the Michael J. Fox Foundation for Parkinson’s Research, which completely supported a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. ANAVEX®3-71, a promising clinical stage therapeutic candidate that targets sigma-1 and muscarinic receptors, has shown disease-modifying effectiveness against the primary hallmarks of Alzheimer’s disease in transgenic mice, including cognitive impairments, amyloid, and tau pathology. ANAVEX®3-71 has proved to be effective against mitochondrial dysfunction and neuroinflammation in preclinical studies.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *